BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares are trading higher Monday. The company provided preliminary, unaudited net revenue figures for Orladeyo (berotralstat) last Friday. What To Know: BioCryst announced its preliminary, unaudited Orladeyo net revenueof $89.9 million for the fourth quarter and full year 2023 net revenue of $325 million last Friday. The company also said that it expects full year 2024 global net Orladeyo revenue to be between $380 million and $400 million. “After three years on the market, Orladeyo continues on a steady growth trajectory to achieve $1 billion at p…